Tecemotide (L-BLP25) in Prostate Cancer

Inclusion Criteria: * Histopathologic documentation of prostate cancer confirmed at the institution of study enrollment prior to starting this study * Newly diagnosed or previously untreated prostate cancer with intermediate or high risk features as defined in the protocol * No evidence of metastatic disease on computed tomography (CT) / magnetic resonance imaging (MRI) or bone scans * No systemic steroid use within 2 weeks prior to initiation of experimental therapy. Limited doses of systemic steroids to prevent intravenous contrast, allergic reaction or anaphylaxis (in subjects who have known contrast allergies) are allowed * Eastern Co-operative Oncology Group (ECOG) performance status of 0-1 * Human leukocyte antigen (HLA)-A2 or A3 positive for immunologic monitoring * Hematological and biochemical eligibility parameters as defined in the protocol * No other active malignancies within the past 3 years (with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder) * Willing to travel to the study center(s) for follow-up visits * Age greater than or equal to 18 years old * Able to understand and sign informed consent * Must agree to use effective birth control (such as a condom) or abstinence during and for a period of 4 months after the last administration of immunotherapy Exclusion Criteria: * No evidence of being immunocompromised by human immunodeficiency virus, a medical condition requiring systemic steroids, a medical condition requiring immunosuppressive therapy, splenectomy * Active Hepatitis B or Hepatitis C * Subjects should have no autoimmune diseases that have required treatment as specified in the protocol * History of immunodeficiency diseases, hereditary or congenital immunodeficiencies * Serious intercurrent medical illness * A clinically significant cardiac disease * Subjects who have received any prior therapy for prostate cancer * Subjects who have known brain metastasis, or with a history of seizures, encephalitis, or multiple sclerosis * Subjects receiving any other investigational agents * Contraindication to biopsy such as bleeding disorders, ratio of prothrombin time to partial thromboplastin time (PT/PTT) \>=1.5 times the upper limit of normal, artificial heart valve * Contraindication to MRI such as subjects weighing \>136 kilograms, allergy to magnetic resonance (MR) contrast agent, subjects with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices * Contraindication to radiation therapy such as pre-existing and active prostatitis or proctitis, inflammatory bowel disease or known genetic sensitivity to ionizing radiation, or history of prior radiation to the pelvis